Incyte Co. (NASDAQ:INCY) Shares Sold by CWM Advisors LLC

CWM Advisors LLC decreased its position in shares of Incyte Co. (NASDAQ:INCY) by 6.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,293 shares of the biopharmaceutical company’s stock after selling 288 shares during the quarter. CWM Advisors LLC’s holdings in Incyte were worth $273,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bremer Trust National Association purchased a new stake in Incyte during the 4th quarter worth about $42,000. Bronfman E.L. Rothschild L.P. lifted its holdings in Incyte by 46.3% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 730 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 231 shares in the last quarter. Edge Wealth Management LLC purchased a new stake in Incyte during the 4th quarter worth about $64,000. Ledyard National Bank purchased a new stake in Incyte during the 4th quarter worth about $80,000. Finally, ETF Managers Group LLC lifted its holdings in Incyte by 15.8% during the 4th quarter. ETF Managers Group LLC now owns 1,564 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

In other Incyte news, EVP Barry P. Flannelly sold 1,000 shares of the stock in a transaction that occurred on Monday, January 28th. The stock was sold at an average price of $80.00, for a total value of $80,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paula J. Swain sold 10,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $87.01, for a total value of $870,100.00. Following the completion of the sale, the executive vice president now owns 38,295 shares of the company’s stock, valued at approximately $3,332,047.95. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,000 shares of company stock worth $2,628,800. 17.10% of the stock is owned by corporate insiders.

Shares of Incyte stock traded down $0.36 during trading on Friday, hitting $73.96. 1,689,855 shares of the stock traded hands, compared to its average volume of 1,328,068. The company has a current ratio of 4.31, a quick ratio of 4.29 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52 week low of $57.00 and a 52 week high of $88.83. The firm has a market capitalization of $15.85 billion, a PE ratio of 90.20 and a beta of 1.39.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.15. Incyte had a return on equity of 6.17% and a net margin of 5.82%. The business had revenue of $528.40 million for the quarter, compared to analyst estimates of $485.72 million. During the same period last year, the company earned $0.02 EPS. Incyte’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, analysts predict that Incyte Co. will post 1.4 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Incyte from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a report on Thursday. BidaskClub cut Incyte from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Barclays restated a “buy” rating and issued a $90.00 target price on shares of Incyte in a research note on Sunday, April 14th. Stifel Nicolaus initiated coverage on Incyte in a research note on Wednesday, April 10th. They issued a “hold” rating and a $82.00 target price on the stock. Finally, Oppenheimer set a $85.00 target price on Incyte and gave the stock a “hold” rating in a research note on Sunday, April 7th. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $91.82.

COPYRIGHT VIOLATION NOTICE: This article was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/cwm-advisors-llc-decreases-holdings-in-incyte-co-incy.html.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Story: How Do Investors Open a Backdoor Roth IRA?

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.